Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
NCT Number: NCT05683899
The purpose of this study is to evaluate the impact of an AI admission prediction tool on the number of preventable hospital admissions, emergency department (ED) length of stay, when the predictions are displayed only to a dedicated ED triage team. Also, to evaluate user perceptions of the AI tool among the triage team users and medical officer of the day users. Additionally, to evaluate any impact of the AI tool on the number of interventions performed by the triage team, and to evaluate the impact of the tool on time-to-admission after an admission order is placed.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Rochester, Minnesota, 55905, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 282 days
Number of avoidable admissions prevented as a fraction of all ED patients in a day, specifically, the number of patients who were seen by the SAPPHIRE triage team and discharged home
Mayo Clinic
Other
Evaluation of Emergency Department AI Prediction Algorithm
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06722040
Children, Emergency Medical Services
Ballerup Municipality, Denmark
View Trial DetailsNCT07412106
Behavior, Cardiovascular Diseases
View Trial DetailsNCT04220671
Hospital Admission, Measles Vaccine
Bissau, Guinea-Bissau
View Trial DetailsNCT07558031
Admission to GIM, Disease Attributes
Montreal, Quebec, Canada
View Trial Details